Comprehensive molecular profiling uses advanced lab methods to study the DNA, RNA, proteins, and other parts of a tumor in detail. This usually involves next-generation sequencing (NGS), which can check thousands of genes at once to find mutations, gene copy increases, fusions, and other genetic changes that relate to cancer.
One example is Caris Life Sciences, a company with one of the largest collections of molecular and clinical data worldwide. They have processed over 849,000 cancer cases and done more than 6.5 million tests to help doctors choose treatments for patients. Their profiling covers 23,000 genes through methods called whole exome and transcriptome sequencing. This gives a broad look at genetic, RNA, and protein data, helping to classify tumors more accurately and predict how patients will respond to treatments.
Comprehensive molecular profiling is very useful in treating cancers like breast cancer, non-small cell lung cancer (NSCLC), biliary tract cancer, and blood cancers. For example, a study in Japan using FoundationOne® CDx NGS panels had a 94.8% success rate in profiling advanced breast cancer tumors. They found actionable mutations in 76% of patients. Some important mutations were in genes like TP53, PIK3CA, and ERBB2. These mutations help doctors use targeted treatments that work better than usual therapies.
In NSCLC, using NGS increased the detection of druggable mutations from 7.9% with local pathology to 25.9% with centralized molecular analysis. KRAS G12C was the most common mutation found. More than one-third of patients had molecular changes that made them eligible for clinical trials. This offers new treatment paths for a cancer that is otherwise hard to treat.
In the United States, networks of cancer centers play a big role in using precision medicine. For example, the Precision Oncology Alliance, led by Caris Life Sciences, has more than 40 cancer centers, including 14 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers. The alliance works to standardize molecular testing and tumor profiling. This helps make advanced diagnostics more available and fair across the country.
Penn State Cancer Institute joined this alliance to bring precision oncology to both academic and community care. They offer treatments like robotic surgery, CAR-T cell therapies, and MRI-guided radiation. Molecular profiling guides which treatments to choose for each patient.
The alliance uses a platform called Molecular Intelligence® that processes DNA, RNA, and protein data with AI tools like DEAN™. This helps doctors pick treatments and find clinical trials faster. Caris Pharmatech works with over 200 research sites and uses Just-In-Time (JIT) trial activation. This reduces delays so sites can be ready for qualified patients in about two weeks.
Artificial intelligence (AI) and automation help manage large and complex data from molecular profiling. Companies such as Caris Life Sciences and BostonGene use AI platforms to analyze genomic, transcriptomic, proteomic, and immune data.
Caris MAI™ (Molecular Artificial Intelligence) looks at data from over 580,000 patient records. It uses machine learning to classify tumors, predict responses, and support treatment choices. This helps reduce the workload on doctors who otherwise have to go through many genetic reports, which might cause some details to be missed.
BostonGene combines molecular and immune system data with its AI platform. The Tumor Portrait™ test gives a full picture of the tumor and its environment. This helps doctors understand how the cancer interacts with immune cells. Knowing this can guide immunotherapy and improve treatment plans.
From an administration point of view, automation also makes processes easier. This includes tracking samples, generating reports, and linking molecular data with electronic health records (EHRs). IT leaders need to ensure systems are secure, support data sharing, and follow HIPAA rules.
Caris Pharmatech’s Just-In-Time trial activation and patient matching speed up access to new treatments. This improves patient care and trial efficiency while reducing delays. It is especially helpful for community hospitals and oncology practices that want to join precision oncology trials.
In breast cancer, wide genomic tests are now common in some centers. They look at tumor mutation burden (TMB) and find mutations like ERBB2 (HER2) amplifications. These tests help use targeted drugs such as trastuzumab. Molecular profiling can also find mutations missed by older tests, so more patients get suitable therapies.
Advanced NSCLC patients gain from centralized molecular testing too. This finds mutations like MET amplifications and RET/ROS1 fusions. Detecting many mutation types helps patients qualify for approved treatments and clinical trials. This is important as cancer treatment changes fast.
For rarer cancers like biliary tract cancer (BTC), genomic profiling is becoming necessary. Research shows different genetic patterns between intrahepatic and extrahepatic cholangiocarcinoma and gallbladder cancer. Mutations like FGFR2 fusions and IDH1/2 in cholangiocarcinoma and ERBB2 changes in gallbladder cancers guide targeted treatments. Some genetic changes also give information about prognosis, aiding clinical care.
These uses show that molecular profiling is not only for common cancers but is useful for many tumor types. Healthcare leaders must make sure molecular testing is available and fits into team care plans.
Delivering precision medicine takes teamwork beyond just molecular testing. Advanced Practice Nurses (APNs) play a growing part in precision health. This includes genetics as well as behavioral, social, and environmental factors that affect care.
Studies in nursing journals highlight the need for APNs to learn genetics, genomics, AI tools, and digital health technology. These skills let them support personalized, predictive, and preventive care. Still, gaps in education and limits in practice rules slow progress.
Healthcare managers should support ongoing training for APNs and other clinicians on genetics and AI to help them work well in precision oncology. Collaboration among nursing, IT, and clinical teams is needed to put precision medicine plans into practice and cover all parts of patient care.
Access to Molecular Profiling Services: Partner with companies like Caris Life Sciences and BostonGene or other certified labs for broad gene panel testing and AI analysis.
Integration with Clinical Workflows: Make sure molecular test reports link well with electronic health records to help doctors make quick, accurate decisions. IT should build secure and compliant systems that reduce manual work and errors.
Staff Training and Education: Train clinicians, especially APNs, oncologists, and pharmacists, on how to read molecular data and understand precision health principles. This helps get the most from molecular profiling.
Supporting Clinical Trial Enrollment: Use automation for choosing trial sites and matching patients through networks like Caris Pharmatech to offer more treatment options and avoid delays.
Data Security and Compliance: Protect genomic data with strong cybersecurity, follow HIPAA rules, and keep lab accreditation current.
Patient Communication: Develop education programs to help patients understand molecular testing results and options for personalized treatment.
Comprehensive molecular profiling is an important part of developing precision medicine for cancer treatment in the United States. It allows for detailed study of tumors to guide tailored treatments, improve trial matching, and lead to better patient outcomes. Networks of cancer centers, AI-based tools, and linking molecular data to health systems help turn molecular information into useful care.
Healthcare administrators, practice owners, and IT managers have a key role in adopting and managing these tools to support a personalized approach to cancer care. As this area grows, continued focus on training, infrastructure, and smooth workflows will be needed to keep up with changes in cancer treatment.
Healthcare groups involved in cancer care in the U.S. can improve precision and patient-centered treatment by putting these molecular testing strategies into practice and supporting their integration with clinical and administrative work.
Caris Life Sciences aims to help improve the lives of individuals by utilizing transformative technologies informed by extensive data to advance precision medicine and enhance patient outcomes.
Caris provides physicians with comprehensive molecular information derived from genomic, transcriptomic, and proteomic data, enabling them to make informed, individualized treatment decisions for their patients.
Caris maintains one of the largest multimodal databases of molecular and clinical outcomes data, consisting of over 580,000 matched patient records.
Molecular profiling allows doctors to pinpoint effective treatments tailored to the individual genetic makeup of a patient’s cancer, leading to improved treatment success.
AI plays a crucial role in Caris by enhancing bioinformatics and machine learning capabilities to analyze massive datasets, classifying cancer molecularly, and predicting patient responses.
Caris offers services that cover the full care continuum, including disease detection, therapy selection, and treatment monitoring, ensuring comprehensive care for cancer patients.
Caris Molecular AI leverages a significant database to create novel solutions for classifying cancer and predicting treatment responses using advanced machine learning techniques.
Caris offers blood-based and tissue-based testing, including whole exome and transcriptome sequencing, to generate insights into a patient’s unique molecular profile.
Early disease detection enhances the chances of successful treatment by identifying cancer at a stage when it is more manageable and treatable.
Caris has processed over 6.5 million tests, measured over 38 billion molecular markers, and holds more than 1,000 publications in the biomedical field.
Simbo is using AI agents to automate all phone related workflows. Connect now to know more.
Schedule AI Agents Demo Now© Since 2019, Simbo AI.
